journal
MENU ▼
Read by QxMD icon Read
search

European Heart Journal Supplements: Journal of the European Society of Cardiology

journal
https://www.readbyqxmd.com/read/30555280/repetitive-levosimendan-treatment-in-the-management-of-advanced-heart-failure
#1
Fabrizio Oliva, Josep Comin-Colet, Francesco Fedele, Friedrich Fruhwald, Finn Gustafsson, Matti Kivikko, Attila Borbély, Gerhard Pölzl, Carsten Tschöpe
Inotropes may be an appropriate treatment for patients with advanced heart failure (AdHF) who remain highly symptomatic despite optimized standard therapies. Objectives for inotrope use in these situations include relief of symptoms and improvement of quality of life, and reduction in unplanned hospitalizations and the costs associated with such episodes. All of these goals must be attained without compromising survival. Encouraging findings with intermittent cycles of intravenous levosimendan have emerged from a range of exploratory studies and from three larger controlled trials (LevoRep, LION-HEART, and LAICA) which offered some evidence of clinical advantage...
December 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/30555279/use-of-levosimendan-in-acute-heart-failure
#2
Veli-Pekka Harjola, George Giannakoulas, Dirk von Lewinski, Simon Matskeplishvili, Alexandre Mebazaa, Zoltan Papp, Robert H G Schwinger, Piero Pollesello, John T Parissis
As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF). Other factors favouring levosimendan in this setting include its extended duration of action due to the formation of an active metabolite and the lack of any attenuation of effect in patients treated with beta-blockers. Effects of levosimendan on systemic haemodynamics include its significant, dose-dependent increases in cardiac output, stroke volume and heart rate, and decreases in right and left ventricular filling and total peripheral resistance...
December 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/30555278/levosimendan-in-acute-and-advanced-heart-failure-still-some-chapters-to-be-written
#3
EDITORIAL
Gerhard Pölzl
No abstract text is available yet for this article.
December 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/29977165/betrixaban-for-prevention-of-venous-thromboembolism-in-acute-medically-ill-patients
#4
Jan Beyer-Westendorf, Peter Verhamme, Rupert Bauersachs
Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity and mortality among acute medically ill patients. More than half of VTE events in this population occur after hospital discharge. Thus, providing extended-duration VTE prophylaxis from in-hospital through the post-discharge continuum may improve the quality of care in patients at risk of VTE. Betrixaban is a new oral, once-daily factor Xa inhibitor approved by the United States (US) Food and Drug Administration (FDA) for extended-duration prophylaxis of VTE in acute medically ill patients...
May 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/29977164/pharmacological-properties-of-betrixaban
#5
Menno V Huisman, Frederikus A Klok
Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-hospital morbidity and mortality. A majority of these VTE events occur post-discharge, and patients remain at increased VTE risk for up to 3 months post-discharge. Recent clinical trials of extended-duration thromboprophylaxis with enoxaparin, rivaroxaban, and apixaban in acute medically ill patients did not demonstrate a net clinical benefit compared with in-hospital thromboprophylaxis, and were shown to be associated with higher risks of major bleeding...
May 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/29977163/reducing-the-burden-of-venous-thromboembolism-in-the-acute-medically-ill-population-with-extended-duration-thromboprophylaxis
#6
Walter Ageno, Beverley J Hunt
Hospitalized acute medically ill patients are vulnerable to venous thromboembolism (VTE), known as hospital-acquired thrombosis (HAT). The elevated risk of HAT is usually due to a combination of factors, with immobility and a prothrombotic state due to acute illness being the most frequent. The HAT risk persists well after hospital discharge, with more than half of events occurring after patient release. These HAT events may be fatal, and patients who survive the initial event may be subject to VTE recurrence, chronic discomfort from post-thrombotic syndrome and, although rare, may develop chronic thrombo-embolic pulmonary hypertension, which is often debilitating...
May 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/29977162/highlights-burden-of-venous-thromboembolism-and-role-of-extended-duration-thromboprophylaxis-in-acute-medically-ill-patients
#7
(no author information available yet)
No abstract text is available yet for this article.
May 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/29977161/extended-thromboprophylaxis-with-betrixaban-a-new-standard-for-acute-medically-ill-patients
#8
EDITORIAL
Alexander T Cohen
No abstract text is available yet for this article.
May 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/29867293/consensus-document-anmco-ance-arca-gicr-iacpr-gise-sicoa-long-term-antiplatelet-therapy-in-patients-with-coronary-artery-disease
#9
Michele Massimo Gulizia, Furio Colivicchi, Maurizio Giuseppe Abrignani, Marco Ambrosetti, Nadia Aspromonte, Gabriella Barile, Roberto Caporale, Giancarlo Casolo, Emilia Chiuini, Andrea Di Lenarda, Pompilio Faggiano, Domenico Gabrielli, Giovanna Geraci, Alessio Gaetano La Manna, Aldo Pietro Maggioni, Alfredo Marchese, Ferdinando Maria Massari, Gian Francesco Mureddu, Giuseppe Musumeci, Federico Nardi, Antonio Vittorio Panno, Roberto Franco Enrico Pedretti, Massimo Piredda, Enrico Pusineri, Carmine Riccio, Roberta Rossini, Fortunato Scotto di Uccio, Stefano Urbinati, Ferdinando Varbella, Giovanni Battista Zito, Leonardo De Luca
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of pharmacologic management of patients with acute coronary syndrome (ACS) and/or those receiving coronary stents. Long-term (>1 year) DAPT may further reduce the risk of stent thrombosis after a percutaneous coronary intervention (PCI) and may decrease the occurrence of non-stent-related ischaemic events in patients with ACS. Nevertheless, compared with aspirin alone, extended use of aspirin plus a P2Y12 receptor inhibitor may increase the risk of bleeding events that have been strongly linked to adverse outcomes including recurrent ischaemia, repeat hospitalisation and death...
May 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/30188961/landiolol-for-managing-atrial-fibrillation-in-post-cardiac-surgery
#10
Jean-Luc Fellahi, Matthias Heringlake, Johann Knotzer, William Fornier, Laure Cazenave, Fabio Guarracino
Landiolol is an intravenous ultra-short acting beta-blocker which has been used in Japan for many years to prevent and/or to treat post-operative atrial fibrillation following cardiac surgery. The drug is now available in Europe. This article is a systematic review of literature regarding the use of landiolol in that specific surgical setting.
January 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/30188960/landiolol-for-managing-atrial-fibrillation-in-intensive-care
#11
Sebastian Rehberg, Michael Joannidis, Tony Whitehouse, Andrea Morelli
Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significantly reduced risk of arterial hypotension and negative inotropic effects. Based on this particular profile along with the clinical experience in Japan for more than a decade landiolol represents a promising agent for the management of elevated heart rate and atrial fibrillation in intensive care patients even with catecholamine requirements...
January 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/30188959/landiolol-pharmacology-and-its-use-for-rate-control-in-atrial-fibrillation-in-an-emergency-setting
#12
Hans Domanovits, Michael Wolzt, Günter Stix
This article provides new insight on landiolol, an ultra-short acting injectable betablocker, recently approved in Europe, with regard to its pharmacokinetic and pharmacodynamic profile, along with its first experience in Caucasian healthy volunteers and patients with atrial fibrillation. Landiolol as iv formulation exhibited in an emergency setting rapid rate reduction in patients with tachycardic atrial fibrillation without pronounced blood pressure drop both in caucasian and asian populations in similar manner...
January 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/30188958/landiolol-for-managing-post-operative-atrial-fibrillation
#13
Martin Balik, Michael Sander, Helmut Trimmel, Gottfried Heinz
Beta-blockers are a potential option to manage peri-operative atrial fibrillation. Landiolol is a new ultra-short beta-blocker with a half-life of only 4 minutes and very high beta-1 selectivity which has been used for treatment and prevention of atrial fibrillation in pulmonary surgery and gastro-intestinal surgery. Due to its limited negative inotropic effect and high beta-1 selectivity landiolol allows for control of heart rate with minimal impact on blood pressure. Landiolol is well tolerated by the respiratory system...
January 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/30188957/landiolol-for-rate-control-management-of-atrial-fibrillation-in-patients-with-cardiac-dysfunction
#14
Stephan von Haehling, Jan Bělohlávek, Fikret Er, Natig Gassanov, Fabio Guarracino, Olivier Bouvet
Atrial fibrillation (AFib) is frequently associated with heart failure. Guidelines for AFib management have been recently updated and include an algorithm for acute heart rate control based on left ventricular ejection fraction and haemodynamics. Landiolol is an injectable ultra-short beta-blocker with very high beta-1 selectivity, listed in Japanese Guidelines for AFib management as potential option for rate control of patient with heart failure. Landiolol is now available in Europe with indication of controlling heart rate in AFib and supraventricular tachycardia...
January 2018: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751851/anmco-aiom-aico-consensus-document-on-clinical-and-management-pathways-of-cardio-oncology-executive-summary
#15
Luigi Tarantini, Michele Massimo Gulizia, Andrea Di Lenarda, Nicola Maurea, Maurizio Giuseppe Abrignani, Irma Bisceglia, Daniella Bovelli, Luisa De Gennaro, Donatella Del Sindaco, Francesca Macera, Iris Parrini, Donatella Radini, Giulia Russo, Angela Beatrice Scardovi, Alessandro Inno
Cardiovascular disease and cancer are leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced survival of cancer patients registered in the last decades and linked to early diagnosis and improvement of care, not infrequently exposes them to the appearance of ominous cardiovascular complications due to the deleterious effects of cancer treatment on the heart and circulatory system...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751850/anmco-sic-sici-gise-sicch-executive-summary-of-consensus-document-on-risk-stratification-in-elderly-patients-with-aortic-stenosis-before-surgery-or-transcatheter-aortic-valve-replacement
#16
Giovanni Pulignano, Michele Massimo Gulizia, Samuele Baldasseroni, Francesco Bedogni, Giovanni Cioffi, Ciro Indolfi, Francesco Romeo, Adriano Murrone, Francesco Musumeci, Alessandro Parolari, Leonardo Patanè, Paolo Giuseppe Pino, Annalisa Mongiardo, Carmen Spaccarotella, Roberto Di Bartolomeo, Giuseppe Musumeci
Aortic stenosis is one of the most frequent valvular diseases in developed countries, and its impact on public health resources and assistance is increasing. A substantial proportion of elderly people with severe aortic stenosis is not eligible to surgery because of the advanced age, frailty, and multiple co-morbidities. Transcatheter aortic valve implantation (TAVI) enables the treatment of very elderly patients at high or prohibitive surgical risk considered ineligible for surgery and with an acceptable life expectancy...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751849/anmco-aiac-sici-gise-sic-sicch-consensus-document-percutaneous-occlusion-of-the-left-atrial-appendage-in-non-valvular-atrial-fibrillation-patients-indications-patient-selection-staff-skills-organisation-and-training
#17
Gavino Casu, Michele Massimo Gulizia, Giulio Molon, Patrizio Mazzone, Andrea Audo, Giancarlo Casolo, Emilio Di Lorenzo, Michele Portoghese, Christian Pristipino, Renato Pietro Ricci, Sakis Themistoclakis, Luigi Padeletti, Claudio Tondo, Sergio Berti, Jacopo Andrea Oreglia, Gino Gerosa, Marco Zanobini, Gian Paolo Ussia, Giuseppe Musumeci, Francesco Romeo, Roberto Di Bartolomeo
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence is increasing due to the progressive aging of the population. About 20% of strokes are attributable to AF and AF patients are at five-fold increased risk of stroke. The mainstay of treatment of AF is the prevention of thromboembolic complications with oral anticoagulation therapy. Drug treatment for many years has been based on the use of vitamin K antagonists, but recently newer and safer molecules have been introduced (dabigatran etexilate, rivaroxaban, apixaban, and edoxaban)...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751848/anmco-position-paper-long-term-follow-up-of-patients-with-pulmonary-thromboembolism
#18
Carlo D'Agostino, Pietro Zonzin, Iolanda Enea, Michele Massimo Gulizia, Walter Ageno, Piergiuseppe Agostoni, Michele Azzarito, Cecilia Becattini, Amedeo Bongarzoni, Francesca Bux, Franco Casazza, Nicoletta Corrieri, Michele D'Alto, Nicola D'Amato, Andrea Maria D'Armini, Maria Grazia De Natale, Giovanni Di Minno, Giuseppe Favretto, Lucia Filippi, Valentina Grazioli, Gualtiero Palareti, Raffaele Pesavento, Loris Roncon, Laura Scelsi, Antonella Tufano
Venous thromboembolism (VTE), including pulmonary embolism and deep venous thrombosis, is the third most common cause of cardiovascular death. The management of the acute phase of VTE has already been described in several guidelines. However, the management of the follow-up (FU) of these patients has been poorly defined. This consensus document, created by the Italian cardiologists, wants to clarify this issue using the currently available evidence in VTE. Clinical and instrumental data acquired during the acute phase of the disease are the cornerstone for planning the FU...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751847/anmco-position-paper-the-use-of-non-vitamin-k-dependent-new-oral-anticoagulant-s-in-pulmonary-embolism-therapy-and-prevention
#19
Iolanda Enea, Loris Roncon, Michele Massimo Gulizia, Michele Azzarito, Cecilia Becattini, Amedeo Bongarzoni, Franco Casazza, Claudio Cuccia, Carlo D'Agostino, Matteo Rugolotto, Marco Vatrano, Eugenio Vinci, Paride Fenaroli, Dario Formigli, Paolo Silvestri, Federico Nardi, Maria Cristina Vedovati, Marino Scherillo
The new oral anticoagulants (NOACs) have radically changed the approach to the treatment and prevention of thromboembolic pulmonary embolism. The authors of this position paper face, in succession, issues concerning NOACs, including (i) their mechanism of action, pharmacodynamics, and pharmacokinetics; (ii) the use in the acute phase with the 'double drug single dose' approach or with 'single drug double dose'; (iii) the use in the extended phase with demonstrated efficacy and with low incidence of bleeding events; (iv) the encouraging use of NOACs in particular subgroups of patients such as those with cancer, the ones under- or overweight, with renal insufficiency (creatinine clearance > 30 mL/min), the elderly (>75 years); (v) they propose a possible laboratory clinical pathway for follow-up; and (vi) carry out an examination on the main drug interactions, their potential bleeding risk, and the way to deal with some bleeding complications...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751846/consensus-document-of-the-italian-association-of-hospital-cardiologists-anmco-italian-society-of-pediatric-cardiology-sicp-and-italian-society-of-gynaecologists-and-obstetrics-sigo-pregnancy-and-congenital-heart-diseases
#20
Innocenzo Bianca, Giovanna Geraci, Michele Massimo Gulizia, Gabriele Egidy Assenza, Chiara Barone, Marcello Campisi, Annalisa Alaimo, Rachele Adorisio, Francesca Comoglio, Silvia Favilli, Gabriella Agnoletti, Maria Gabriella Carmina, Massimo Chessa, Berardo Sarubbi, Maurizio Mongiovì, Maria Giovanna Russo, Sebastiano Bianca, Giuseppe Canzone, Marco Bonvicini, Elsa Viora, Marco Poli
The success of cardiac surgery over the past 50 years has increased numbers and median age of survivors with congenital heart disease (CHD). Adults now represent two-thirds of patients with CHD; in the USA alone the number is estimated to exceed 1 million. In this population, many affected women reach reproductive age and wish to have children. While in many CHD patients pregnancy can be accomplished successfully, some special situations with complex anatomy, iatrogenic or residual pathology are associated with an increased risk of severe maternal and fetal complications...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
journal
journal
34647
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"